Amarin's stock takes hit after SEC filing about patents on lead drug; Argos Therapeutics' IPO delayed;

@FierceBiotech: NIH backs effort to integrate clinical trials data into EHRs. Story | Follow @FierceBiotech

@JohnCFierce: ACT's trying a reverse split in the range of 1/20, 1/80 to get onto Nasdaq. Often hyped but interesting stem cell work. Release | Follow @JohnCFierce

@RyanMFierce: Worth the 5 mins to read @ldtimmerman 's interview with former Amgen R&D chief Roger Perlmutter. Interview | Follow @RyanMFierce

@FierceMedDev: Cipla introduces new pain-free screening tech for early detection of breast cancer in India. Story | Follow @FierceMedDev

@MarkHFierce: Researchers found five gene mutations connected to elevated blood platelet levels in African-Americans. Big finding. Release | Follow @MarkHFierce

> TG Therapeutics said that it has raised $25 million in financing, licensed worldwide rights to the CD20-targeting antibody drug Ublituximab from LFB Biotechnologies and GTC Biotherapeutics, and has made a deal to become a public company through a merger with Manhattan Pharmaceuticals ($TGTX). Release

> Amarin's ($AMRN) stock was down 11% late this morning after the company filed info with the SEC about its efforts to protect the intellectual property for its potential blockbuster cardiovascular disease drug AMR101. Filing

> Ex-Pfizer ($PFE) R&D chief John LaMattina counters the belief that drug discovery has become more difficult. Blog

> Argos Therapeutics has delayed its plans for an initial public offering, according to Renaissance Capital. Item

> Advanced Cell Technology ($ACTC) revealed plans for a reverse stock split that it hopes increases its share price enough to gain listing on the Nasdaq Global Market. Release

> Xconomy's Luke Timmerman profiles South San Francisco-based startup Cytomx Therapeutics, which has ambitious plans to engineer anti-cancer antibody drugs that are more potent than offerings from Eli Lilly ($LLY) and Amgen ($AMGN). Article

> Arena Pharmaceuticals ($ARNA) has filed paperwork to formally request European approval of its weight drug Lorcaserin. Release

Pharma News

@FiercePharma: China pharmaceuticals feel bite of healthcare reforms. Story via @Reuters | Follow @FiercePharma

> Chinese pharmas feel the squeeze of healthcare reform. Story

> Columbia Labs to cut 42% of workforce after FDA snub. News

> Indian regulators, alleging overpricing, demand $86M from Cipla. Article

> Sources: Nestle leads in Pfizer unit bid, but don't count out Danone-Mead. Piece

And Finally… Amid budgetary woes, NASA is regrouping to fund the U.S. space agency's mission to Mars. News

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.